PLYMOUTH MEETING, Pa., May 25, 2023 /PRNewswire/ INOVIO , a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related. | May 25, 2023
Operator: Good day and welcome to the Inovio First Quarter 2022 Financial Results Conference Call. All participants will be in a listen-only mode for the duration of the call.
Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients Second cohort of trial showed 10 of the.